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Abstract
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring
in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may
decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed
variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into
groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was
estimated using the Kaplan–Meier method and compared with reported rates in cohorts treated with contemporary
chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was
48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups,
respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an
estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the
low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients
with DLBCL is associated with a lower-than-expected rate of CNS relapse.
Introduction
Relapse of aggressive non-Hodgkin lymphoma (NHL) in
the central nervous system (CNS) is an uncommon but
serious and potentially fatal event. Incidence rates of up to
10% have been reported1–4. The addition of rituximab to
standard CHOP therapy (R-CHOP; cyclophosphamide,
doxorubicin, vincristine, prednisone) has contributed to a
reduction in both systemic and CNS relapse5–7. It is
important to note however that the blood–brain barrier
(BBB) renders the CNS a sanctuary site where penetration
by standard chemoimmunotherapy is insufficient. Given
the poor outcome of CNS relapse, there is clearly a need
to incorporate agents that cross the BBB in upfront
regimens to mitigate the risk of this event.
A number of factors are associated with an increased
risk of developing CNS relapse in NHL such as older age,
advanced stage, extranodal disease, elevated lactate
dehydrogenase (LDH), and renal/adrenal involvement3,8.
The CNS-International Prognostic Index (CNS-IPI) is a
validated scoring system3 that risk-stratifies patients with
diffuse large B-cell lymphoma (DLBCL) and may poten-
tially help identify those at higher risk of developing CNS
relapse.
Lenalidomide, an immunomodulatory agent that pene-
trates the CNS, has shown promise in relapsed/refractory
(R/R) aggressive NHL, with well-demonstrated single-
agent activity and tolerability9,10. Specifically, lenalidomide
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is active and well-tolerated in heavily pre-treated CNS
lymphoma11. Combination therapy with lenalidomide
(with bendamustine/rituximab (BR) or R-CHOP) has also
been shown to be effective and tolerable in both the
upfront and R/R settings12–14. Given its ability to cross the
BBB, we hypothesized that lenalidomide would lower the
risk of CNS relapse when included in induction therapy. In
this study, we evaluated and characterized the incidence of
isolated CNS relapse in a combined cohort of DLBCL
patients treated with upfront lenalidomide plus R-CHOP
(R2CHOP).
Methods
Patients with histologically confirmed DLBCL treated
with R2CHOP who were enrolled in two phase 2 trials—
Mayo Clinic (MC)15 (NCT00670358) and Fondazione
Italiana Linfomi (FIL)12 (NCT00907348)—were included
in this study. Several patients (n= 23) in the MC cohort
whose histology excluded them from the final trial ana-
lysis (owing to histologic transformation or composite
lymphoma) were included in this analysis, as they were
allowed to remain on study following a protocol amend-
ment. All patients had positron emission tomography
(PET) imaging prior to and after completion of therapy,
but not brain magnetic resonance imaging. Accordingly,
patients were deemed to have no CNS involvement at
baseline by clinical assessment and PET imaging only.
Data collected from patient records included age, gen-
der, disease stage, status at last follow-up, cell of origin
(COO) based on immunohistochemistry according to
Hans’ algorithm, LDH level, extranodal site involvement,
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, and administration of CNS prophylaxis.
The protocol for each trial allowed intrathecal (IT) che-
motherapy for prophylactic purposes per local practice
(MC uses methotrexate 12mg IT for 6 doses, FIL uses
methotrexate 12mg, or 15mg IT for 4–6 doses). No
systemic CNS prophylaxis was allowed.
Risk stratification
The combined cohort of patients was stratified into
three risk groups based on calculated CNS-IPI score. This
scoring tool uses independent variables (age, stage, LDH
level, ECOG performance status, extranodal sites, adre-
nal/kidney involvement) to classify patients into low
(score 0–1), intermediate (score 2–3), and high (score
4–6) risk of CNS relapse3.
Statistical methods
Kruskal–Wallis or chi-square test was used to compare
the three risk groups in terms of various clinical variables
including age, stage, COO, LDH level, extranodal site
involvement, ECOG performance status, and adminis-
tration of CNS prophylaxis. The Kaplan–Meier method
was used for time-to-event analyses. SAS® software (ver-
sion 9.4 M3) was used for all statistical analyses.
Comparison with other cohorts
We compared the Kaplan–Meier estimated 2-year CNS
relapse rates of R2CHOP patients for each of the CNS-IPI
risk groups (low, intermediate, and high), and also for the
entire cohort, to rates published for patients treated with
contemporary R-CHOP. The comparison cohorts inclu-
ded the R-CHOP-treated cohort of the Molecular Epi-
demiology Resource (MER) of the University of Iowa/
Mayo Clinic Specialized Program of Research Excellence
database, as reported by Thanarajsingam and colleagues16,
as well as two large DLBCL cohorts treated with con-
temporary chemoimmunotherapy, (German High-Grade
Non-Hodgkin Lymphoma Study Group/MabThera
International Trial (DSHNHL/MInT) and British
Columbia Cancer Agency (BCCA) DLBCL cohorts), as
reported by Schmitz et al.3 Data for the R-CHOP-treated
cohort of the MER was obtained through direct corre-
spondence and discussion with the authors of that study,
whereas data pertaining to the CNS relapse rates for the
DSHNHL/MInT and BCCA DLBCL cohorts was obtained
directly from the publication for that report.
Results
A total of 136 patients with DLBCL (87 MC patients,
49 FIL patients) were included in this study (Table 1).
Mean age was 65 and median follow-up in 104 patients
that were still alive at the time of the analysis was
48.2 months (range: 2.1–88.5).
When categorized into risk groups per the CNS-IPI
score, 14 (10.3%), 97 (71.3%), and 25 (18.4%) patients were
classified into low, intermediate, and high-risk groups,
respectively (Fig. 1). Comparison between these groups
across different variables is shown in Table 2.
Of the 136 patients, only one developed isolated CNS
relapse (which was parenchymal in nature), yielding an
incidence rate of 0.007 (0.7%). His disease at diagnosis was
consistent with a GCB phenotype, extensive extranodal
disease primarily involving multiple bony sites, and a
calculated CNS-IPI score of 4 (high risk). Time to
development of CNS relapse from diagnosis in this par-
ticular patient was 10 months and the relapse occurred
6 months after achieving a complete response (CR) by
PET imaging. He was taken off protocol and salvaged with
a high-dose methotrexate regimen followed by autologous
stem cell transplantation.
The estimated 2-year CNS relapse rates by
Kaplan–Meier method are 0.9% for the entire R2CHOP
cohort and 0, 0, and 5.0% for the low, intermediate, and
high-risk groups, respectively. When compared with
contemporary DLBCL patients treated with R-CHOP
from the MER database, the overall 2-year CNS relapse
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rate in the R2CHOP cohort is lower (0.9 vs. 1.8%,
Table 3). Similarly, the 2-year CNS relapse rates across
risk groups, and overall, are lower for the R2CHOP cohort
compared with the DLBCL cohorts from DSHNHL/MInT
and BCCA (Table 3), as reported by Schmitz et al.3.
Discussion
CNS relapse in DLBCL continues to occur in a sig-
nificant minority of patients and carries a poor prognosis
even in the era of modern chemoimmunotherapy.
Improvements in upfront regimens are needed to prevent
lymphoma relapse in this sanctuary site. We report a
critical observation in this analysis of a combined cohort
of DLBCL patients treated with R2CHOP. Although CNS
relapse rates with contemporary therapy have been
roughly reported to range up to 5%17, we note a con-
siderably lower rate of 0.7%. The median follow-up
duration of 48.2 months is adequate to identify CNS
events, as most cases of CNS relapse tend to occur within
a few months from diagnosis4. It is worth noting that this
lower-than-expected CNS relapse rate is observed in a
population that is mostly intermediate and high risk (n=
122, 89.7%) by CNS-IPI score.
Our analysis reveals considerable practice variation with
regard to the use of prophylactic IT methotrexate, with
significantly more patients having received IT che-
motherapy in the FIL cohort compared with the MC
cohort. This reflects regional and institutional differences
in the administration of CNS prophylaxis, which is often
based on the provider’s judgement. This variation in
practice is one of our study’s limitations since it can
contribute to confounding bias. Interestingly, however,
several studies have suggested that IT chemoprophylaxis
is ineffective in reducing the risk of CNS relapse1,18,19. As
such, we believe that the lack of standardization in pro-
phylactic IT methotrexate practice did not have a sig-
nificant impact on our analysis. Another limitation of our
study is the relatively small number of patients in the
combined cohorts. Furthermore, neither trial was pow-
ered to assess for CNS events as CNS relapse was not a
particular outcome measure in the study protocols.
There continues to be significant variability and con-
troversy with regard to optimal CNS prophylaxis strate-
gies. This lack of consensus is driven primarily by lack of
strong evidence for benefit of current strategies and the
difficulty of conducting definitive randomized studies in
this area20. Recent practice trends tend to favor systemic
Table 1 Baseline patient characteristics
FIL MC Total
(n = 49) (n = 87) (n = 136)
Age
Median 69 65 68
Range (61.0–79.0) (19.0–87.0) (19.0–87.0)
Clinical stage
2 6 (12.2%) 13 (14.9%) 19 (14.0%)
3 8 (16.3%) 21 (24.1%) 29 (21.3%)
4 35 (71.4%) 53 (60.9%) 88 (64.7%)
Cell of origin
GCB 16 (32.7%) 43 (49.4%) 59 (43.4%)
Non-GCB 16 (32.7%) 34 (39.1%) 50 (36.8%)
NA 17 (34.7%) 10 (11.5%) 27 (19.9%)
LDH above ULN
No 26 (53.1%) 34 (39.1%) 60 (44.1%)
Yes 23 (46.9%) 53 (60.9%) 76 (55.9%)
Extranodal sites
0 or 1 31 (63.3%) 64 (73.6%) 95 (69.9%)
>1 site 18 (36.7%) 23 (26.4%) 41 (30.1%)
Performance status
0 17 (34.7%) 43 (49.4%) 60 (44.1%)
1 25 (51.0%) 35 (40.2%) 60 (44.1%)
2 7 (14.3%) 9 (10.3%) 16 (11.8%)
CNS prophylaxis
No 30 (61.2%) 86 (98.9%) 116 (85.3%)
Yes 19 (38.8%) 1 (1.1%) 20 (14.7%)
CNS-IPI score
Low 0 (0.0%) 14 (16.1%) 14 (10.3%)
Intermediate 37 (75.5%) 60 (69.0%) 97 (71.3%)
High 12 (24.5%) 13 (14.9%) 25 (18.4%)
GCB germinal center B-cell, NA not available, ULN upper limit of normal, MCMayo
Clinic, FIL Fondazione Italiana Linfomi
Fig. 1 Patient flow diagram. MC=Mayo Clinic. FIL= Fondazione
Italiana Linfomi
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intravenous (IV) methotrexate over IT therapy21,22.
Although prophylactic IV methotrexate is gaining popu-
larity, it tends to be costly and inconvenient and has the
potential for serious toxicity. Our study suggests the
potential prophylactic benefit of utilizing lenalidomide, an
orally bioavailable CNS-penetrating agent, when com-
bined with R-CHOP in the upfront setting. The two phase
2 trials analyzed in this study have already demonstrated
safety and manageable toxicity of such a combination.
Further assessment of the utility of lenalidomide in
reducing CNS relapse risk in DLBCL is warranted.
Effective stratification of patients and identification of
those at higher risk will likely involve both clinical and
molecular parameters. At present, two phase 3 trials
evaluating the combination of lenalidomide and R-CHOP
in DLBCL patients are underway (ECOG1412
(NCT01856192) and ROBUST (NCT02285062)). Char-
acterization of CNS events in these trials will be helpful in
confirming the findings we noted in this analysis.
Our finding that frontline R2CHOP may lower the risk
of CNS relapse in patients with DLBCL supports an
ongoing trend in clinical studies where other novel small
molecules are being investigated in the upfront setting in
combination with R-CHOP, such as ibrutinib
(NCT01855750), venetoclax (NCT02055820), and ever-
olimus23 (NCT01334502). The impact of such R(X)CHOP
combinations24 (where X represents a novel agent mole-
cule) on CNS relapse is yet to be defined.
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Table 2 Baseline patient characteristics by CNS-IPI score
High risk Intermediate risk Low risk P value
(n = 25) (n = 97) (n = 14)
Age 0.0014
Median 69 69 56.5
Range (55.0–83.0) (19.0–87.0) (24.0–79.0)
Clinical stage < 0.0001
2 0 (0.0%) 13 (13.4%) 6 (42.9%)
3 0 (0.0%) 25 (25.8%) 4 (28.6%)
4 25 (100.0%) 59 (60.8%) 4 (28.6%)
Cell of origin 0.2353
GCB 7 (28.0%) 47 (48.5%) 5 (35.7%)
Non-GCB 10 (40.0%) 35 (36.1%) 5 (35.7%)
NA 8 (32.0%) 15 (15.5%) 4 (28.6%)
LDH above ULN <0.0001
No 2 (8.0%) 45 (46.4%) 13 (92.9%)
Yes 23 (92.0%) 52 (53.6%) 1 (7.1%)
Extranodal sites <0.0001
0 or 1 2 (8.0%) 79 (81.4%) 14 (100.0%)
>1 site 23 (92.0%) 18 (18.6%) 0 (0.0%)
Performance status <0.0001
0 5 (20.0%) 45 (46.4%) 10 (71.4%)
1 9 (36.0%) 47 (48.5%) 4 (28.6%)
2 11 (44.0%) 5 (5.2%) 0 (0.0%)
CNS prophylaxis <0.0001
No 14 (56.0%) 88 (90.7%) 14 (100.0%)
Yes 11 (44.0%) 9 (9.3%) 0 (0.0%)
Based on CNS-IPI score, patients are classified into low (0–1), intermediate (2–3),
or high (4–6) risk of CNS relapse
GCB germinal center B-cell, NA not available, ULN upper limit of normal
Table 3 Estimated 2-year CNS relapse rate per risk group across cohorts
Two-year CNS relapse rates, estimated by Kaplan–Meier method
Risk group DSHNHL/MInT DLBCL cohorta BCCA DLBCL cohorta MER R-CHOP cohortb MC/FIL R2CHOP cohort
Low 0.8% (95% CI: 0.2–1.4%) 0.8% (95% CI: 0.0–1.6%) 1.4% (95% CI: 0.5–3.7%) 0% (95% CI: 0.0–0.0%)
Intermediate 2.9% (95% CI: 1.5–4.3%) 3.9% (95% CI: 2.3–5.5%) 2.2% (95% CI: 1.2–4.2%) 0% (95% CI: 0.0–0.0%)
High 10.0% (95% CI: 5.7–14.3%) 12.0% (95% CI: 7.9–16.1%) 1.1% (95% CI: 0.2–8.1%) 5.0% (95% CI: 0.0–14.1%)
Overall Not available 4.8% (95% CI: 3.6–6.0%) 1.8% (95% CI: 1.1–3.0%) 0.9 % (95% CI: 0.0–2.6%)
MC/FIL Mayo Clinic/Fondazione Italiana Linfomi, DSHNHL/MInT German High-Grade Non-Hodgkin Lymphoma Study Group/ MabThera International Trial, BCCA British
Columbia Cancer Agency, MER Molecular Epidemiology Resource of the University of Iowa/Mayo Clinic Specialized Program of Research Excellence.
aAs reported by Schmitz et al.3
bAs reported by Thanarajasingam et al.16
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